Translate Bio, Inc.: management transactions · United States · SEC (Form 4)

About Translate Bio, Inc.

Translate Bio, Inc. was a U.S.-based biopharmaceutical company focused on messenger RNA (mRNA) therapeutics and vaccines. It was listed in the United States on the NASDAQ under ticker TBIO, and its historical operational base was in Lexington, Massachusetts. For investors, the company fit squarely into the high-risk, high-science segment of biotech: it was a clinical-stage developer rather than a commercial drug maker, with value creation driven primarily by research progress, partnership milestones, and regulatory execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1693415/000120919121056057/0001209191-21-056057-index.htm?utm_source=openai)) Translate Bio was built around a differentiated mRNA platform intended to address diseases caused by protein or gene dysfunction and to prevent infectious diseases by generating protective immunity. The company reached public markets through its IPO in 2018, after which its filings consistently described it as a clinical-stage mRNA therapeutics business. That positioning made it a specialized player in a field that attracted increasing investor attention as mRNA became one of the most important technological themes in modern biotech. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1693415/000156459019008803/tbio-10k_20181231.htm?utm_source=openai)) Its core business lines were centered on two broad areas: therapeutic programs and vaccine programs based on mRNA. In practice, the company’s most important strategic partnership was with Sanofi, which supported development efforts across selected programs. This type of collaboration-based model is common in emerging biotech: it reduces the burden of standalone commercialization, but it also means the company’s valuation is highly sensitive to clinical data, partner commitment, and the ability to advance assets toward proof of concept. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1693415/000119312521247021/d117934dsc14d9.htm?utm_source=openai)) From a competitive standpoint, Translate Bio occupied a niche within the mRNA ecosystem. Compared with large pharmaceutical companies, it lacked scale and commercial breadth, but it had scientific focus and platform purity. For equity analysts, the key questions were whether the platform could generate clinically meaningful data, whether the partnership with Sanofi could unlock broader pipeline value, and whether the company could translate research momentum into durable economic returns. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1693415/000119312521234062/d191890dex993.htm?utm_source=openai)) A major recent development was Sanofi’s acquisition of Translate Bio in 2021. Sanofi announced the definitive agreement in August 2021 and later completed the acquisition in September 2021, effectively ending Translate Bio’s life as an independent public company. That fact matters materially for current market context: although historical SEC Form 4 insider transactions may still exist, TBIO is no longer an ongoing standalone listed equity story. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1693415/000119312521234062/d191890dex993.htm?utm_source=openai))